Therapeutic area intelligence for Hormone Replacement Therapy with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Recent signals(4)

RegulatoryJuly 14, 2026

FDA Grants Approval for Estradiol ANDA218214 by Encube

The FDA has granted approval for ANDA218214, a generic estradiol product submitted by Encube.

ClinicalJuly 10, 2026

Optimizing Estradiol Levels for Menopausal Health: Implications for Hormone Therapy

The study identifies optimal estradiol serum levels that alleviate vasomotor symptoms while also assessing impacts on osteoporosis and cardiovascular health.

ClinicalJune 28, 2026

Pilot study compares transdermal and oral HRT effects on bone density in Turner syndrome

The study evaluates the impact of oral versus transdermal hormone replacement therapy on bone mineral density in women with Turner syndrome.

RegulatoryJune 21, 2026

FDA Approves Supplement for Estradiol by Mylan Technologies

The FDA has approved a supplemental application for estradiol submitted by Mylan Technologies.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.